These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 11815995)
1. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features. Shpitz B; Bomstein Y; Sternberg A; Klein E; Tiomkin V; Kaufman A; Groisman G; Bernheim J J Surg Oncol; 2002 Feb; 79(2):86-92. PubMed ID: 11815995 [TBL] [Abstract][Full Text] [Related]
2. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Esposito NN; Mohan D; Brufsky A; Lin Y; Kapali M; Dabbs DJ Arch Pathol Lab Med; 2006 Oct; 130(10):1516-21. PubMed ID: 17090194 [TBL] [Abstract][Full Text] [Related]
3. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast. Kleer CG; Giordano TJ; Braun T; Oberman HA Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524 [TBL] [Abstract][Full Text] [Related]
4. Expression of p53 protein and Ki-67 antigen in phyllodes tumor of the breast. Chan YJ; Chen BF; Chang CL; Yang TL; Fan CC J Chin Med Assoc; 2004 Jan; 67(1):3-8. PubMed ID: 15077883 [TBL] [Abstract][Full Text] [Related]
5. Importance of P53, Ki-67 expression in the differential diagnosis of benign/malignant phyllodes tumors of the breast. Kucuk U; Bayol U; Pala EE; Cumurcu S Indian J Pathol Microbiol; 2013; 56(2):129-34. PubMed ID: 24056649 [TBL] [Abstract][Full Text] [Related]
6. p53 and Ki-67 expression as prognostic factors in cystosarcoma phyllodes. Erhan Y; Zekioglu O; Ersoy O; Tugan D; Aydede H; Sakarya A; Kapkaç M; Ozdemir N; Ozbal O; Erhan Y Breast J; 2002; 8(1):38-44. PubMed ID: 11856160 [TBL] [Abstract][Full Text] [Related]
7. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904 [TBL] [Abstract][Full Text] [Related]
8. Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: immunohistochemical and flow cytometric study of 118 cases. Niezabitowski A; Lackowska B; Rys J; Kruczak A; Kowalska T; Mitus J; Reinfuss M; Markiewicz D Breast Cancer Res Treat; 2001 Jan; 65(1):77-85. PubMed ID: 11245343 [TBL] [Abstract][Full Text] [Related]
9. [Clinicopathologic features and prognostic factors of malignant phyllodes tumors]. Jia C; Mei F; Zheng J; You JF; Liu JY Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):729-34. PubMed ID: 24447548 [TBL] [Abstract][Full Text] [Related]
10. Expression of cancer stem cell markers in breast phyllodes tumor. Kim SI; Koo JS Cancer Biomark; 2020; 29(2):235-243. PubMed ID: 32675396 [TBL] [Abstract][Full Text] [Related]
11. An approach to malignant mammary phyllodes tumors detection. Ilić I; Randelović P; Ilić R; Katić V; Milentijević M; Velicković L; Krstić M Vojnosanit Pregl; 2009 Apr; 66(4):277-82. PubMed ID: 19441158 [TBL] [Abstract][Full Text] [Related]
12. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956 [TBL] [Abstract][Full Text] [Related]
13. Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. Chen WH; Cheng SP; Tzen CY; Yang TL; Jeng KS; Liu CL; Liu TP J Surg Oncol; 2005 Sep; 91(3):185-94. PubMed ID: 16118768 [TBL] [Abstract][Full Text] [Related]
14. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration. Kim GE; Kim NI; Park MH; Lee JS Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739 [TBL] [Abstract][Full Text] [Related]
15. Analysis of phyllodes tumor recurrence according to the histologic grade. Kim S; Kim JY; Kim DH; Jung WH; Koo JS Breast Cancer Res Treat; 2013 Oct; 141(3):353-63. PubMed ID: 24062207 [TBL] [Abstract][Full Text] [Related]
16. Phyllodes tumors of the breast: clinicopathological analysis of 106 cases from a single institution. Efared B; Ebang GA; Tahiri L; Sidibé IS; Erregad F; Hammas N; Melhouf MA; Banani A; Chbani L; Fatemi HE Breast Dis; 2018; 37(3):139-145. PubMed ID: 29332027 [TBL] [Abstract][Full Text] [Related]
17. Ki67 and P53 Expression in Relation to Clinicopathological Features in Phyllodes Tumour of the Breast. Mohd Ali NA; Nasaruddin AF; Mohamed SS; Wan Rahman WF Asian Pac J Cancer Prev; 2020 Sep; 21(9):2653-2659. PubMed ID: 32986365 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast. Spanheimer PM; Murray MP; Zabor EC; Stempel M; Morrow M; Van Zee KJ; Barrio AV Ann Surg Oncol; 2019 Jul; 26(7):2136-2143. PubMed ID: 30783853 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma. Suthipintawong C; Wejaranayang C; Vipupinyo C J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508 [TBL] [Abstract][Full Text] [Related]
20. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein. Moriki T; Takahashi T; Tanioka F; Yamane T; Hara H Pathol Res Pract; 1995 Nov; 191(11):1122-32. PubMed ID: 8822114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]